Lo WL, Liang CH, Chen LC, Lee SY, Lo SN, Chen MW, Lu RM, Liu IJ, Wu HC, Chang CH. Imaging and biodistribution of radiolabeled SP90 peptide in
BT-483 tumor bearing mice.
Appl Radiat Isot 2020;
161:109162. [PMID:
32561130 DOI:
10.1016/j.apradiso.2020.109162]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 03/22/2020] [Accepted: 03/27/2020] [Indexed: 01/01/2023]
Abstract
The objective of this study was to evaluate radiolabeled DOTA-SP90 as a radiotracer for breast cancer. The in vitro competition assay showed that radiolabeled DOTA-SP90 had significant binding affinity to BT-483 cancer cells. Biodistribution, nanoSPECT/CT and nanoPET/CT imaging results indicated that radiolabeled DOTA-SP90 can accumulate in tumors. In addition, radiolabeled DOTA-SP90 peptides can also detect metastatic tumors. Therefore, radiolabeled SP90 peptide may provide the potential capability as diagnostic agent for breast cancer patients.
Collapse